FIELD: biotechnology.
SUBSTANCE: bispecific single-chain antibody molecule comprising the first binding domain capable of binding to an epitope of the CD3 (Epsilon)-chain of human and common marmoset (Callithrix jacchus), oedipus tamarins (Saguinis oedipus) or common squirrel monkey (Saimiri sciureus), wherein said epitope comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu (QDGNE) and a second binding domain capable of binding to a specific membrane antigen of human (PSMA) and cynomolgus monkey prostate, is proposed. Also are described nucleic acid encoding a bispecific single chain antibody molecule, a host cell and a method for producing the bispecific single chain antibody molecule of the invention. Also are considered a pharmaceutical composition for the prevention, treatment or amelioration of cancer associated with the expression of PSMA, and the application of the bispecific single chain antibody molecule for manufacturing of such pharmaceutical composition.
EFFECT: invention may find further application in the treatment of diseases associated with the PSMA.
16 cl, 2 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PSMA×CD3 BISPECIFIC SINGLE-CHAIN ANTIBODY HAVING INTERSPECIES SPECIFICITY | 2009 |
|
RU2559531C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
| BISPECIFIC BINDING AGENTS WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2535992C2 |
| CD3-EPSILON-BINDING DOMAIN HAVING INTERSPECIES SPECIFICITY | 2008 |
|
RU2561457C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| SOLUBLE CD3 STABLE PHARMACEUTICAL COMPOSITIONS | 2006 |
|
RU2426743C2 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
| LY6G6D ANTIBODIES AND METHODS OF USE | 2020 |
|
RU2818569C1 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
